AbbVie is a global biopharmaceutical company that discovers, develops, manufactures, and sells a broad portfolio of prescription medicines. It derives most revenue from branded drugs sold to healthcare providers, hospitals, and patients, with notable products such as HUMIRA, SKYRIZI, and RINVOQ contributing meaningful shares. The company benefits from a robust pipeline and established brands but faces patent expirations and competition from biosimilars and generics that threaten long-term pricing power. Its scale and diversified geographic footprint support its commercial reach and operational resilience.
—
AbbVie is a global biopharmaceutical company that discovers, develops, manufactures, and sells a broad portfolio of prescription medicines. It derives most revenue from branded drugs sold to healthcare providers, hospitals, and patients, with notable products such as HUMIRA, SKYRIZI, and RINVOQ contributing meaningful shares. The company benefits from a robust pipeline and established brands but faces patent expirations and competition from biosimilars and generics that threaten long-term pricing power. Its scale and diversified geographic footprint support its commercial reach and operational resilience.
—
Daily adjusted close
AbbVie is a global biopharmaceutical company that discovers, develops, manufactures, and sells a broad portfolio of prescription medicines. It derives most revenue from branded drugs sold to healthcare providers, hospitals, and patients, with notable products such as HUMIRA, SKYRIZI, and RINVOQ contributing meaningful shares. The company benefits from a robust pipeline and established brands but faces patent expirations and competition from biosimilars and generics that threaten long-term pricing power. Its scale and diversified geographic footprint support its commercial reach and operational resilience.